Interactions of Epstein-Barr virus with Leukocytes of chronic lymphocytic leukemia patients by Dreyfus, James Nathaniel
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
1978
Interactions of Epstein-Barr virus with Leukocytes
of chronic lymphocytic leukemia patients
James Nathaniel Dreyfus
Yale University
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Dreyfus, James Nathaniel, "Interactions of Epstein-Barr virus with Leukocytes of chronic lymphocytic leukemia patients" (1978). Yale
Medicine Thesis Digital Library. 2538.
http://elischolar.library.yale.edu/ymtdl/2538
VALE MEDICAL LIBRARY 
3 9002 08627 9123 
YALE 
MEDICAL LIBRARY 
Digitized by the Internet Archive 
in 2017 with funding from 
The National Endowment for the Humanities and the Arcadia Fund 
https://archive.org/details/interactionsofepOOdrey 



INTERACTIONS OF EPSTEIN-BARR VIRUS WITH LEUKOCYTES 
OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS 
James Nathaniel Dreyfus 
A.B., Harvard College 
A Thesis Submitted to the Yale University School of Medicine 
In Partial Fulfillment of the Requirements for the Degree 
Of Doctor of Medicine 
May, 1978 
ci L 1 5 
T 113 
YiX 
3350 
table of contents 
I. Introduction P- 1 
II. Materials and Methods P- 18 
III. Results P- 25 
IV. Discussion P- 33 
V. Tables P- 39 
VI. Appendix P- 51 
VII. References P- 53 

Acknowledgments 
I would like to record my deepest appreciation to those individuals 
whose assistance made possible this thesis: 
Dr. James Robinson, thesis advisor and friend, who offered me 
enthusiasm, ideas, encouragement, and much of his time. 
Dr. George Miller, who stimulated my interest in EBV, supported 
my efforts, and provided critical advice. 
Dr. Sally Marchesi, Dr. Paul Lebowitz, and the attending staff of 
the Department of Hematology who facilitated the obtaining of samples. 
Lee Heston and the other members of the research group who 
furnished valuable technical assistance and advice. 
My wife, Ellen, who was understanding and encouraging throughout 
this long process. 
The patients. 
,iG 
Jr '■ 3 .. . /'t ' ~ Oids >. GV f ■ 
. •=? . 
INTRODUCTION 
Statement of the Problem 
Epstein-Barr virus (EBV), a member of the herpes-virus group, is the 
etiologic agent of infectious mononucleosis and is a candidate as the cause 
of Burkitt lymphoma and nasopharyngeal carcinoma. (Reviewed by Miller, 
1975; Miller, 1974 .) Discovered in 1964 in a cell line from a Burkitt lympho 
ma patient, EBV was the first virus to be regularly linked with a human malig¬ 
nant tumor. This finding together with the serendipitous observation in 1968 
that infectious mononucleosis is associated with EBV sero-conversion (Ilenle 
et al., 1968), has stimulated a vast amount of research on the virus and its 
relationship to a spectrum of disease from inapparent infection to malignancy. 
In cell culture, EBV strains demonstrate two biologic properties. The 
first is "transformation" or what Miller has alternatively termed "immorta¬ 
lization" (Ilenle et al., 1967; Pope et al., 1969; Gerber et al., 1969; 
Miller et al., 1971). EBV causes normal human lymphocytes and certain non¬ 
human primate lymphocytes with a limited life span in vitro to form continuous 
i.e., immortal, cell lines with a lymphoblastoid appearance. Preceding the 
establishment of cell lines, EBV stimulates cellular DNA synthesis. This 
stimulation can be quantified and used as an indicator of immortalization. 
(Robinson and Miller, 1975). 
The second property is termed "superinfection". (Miller et al., 1974 ). 
When the P3JHR1 strain of EBV is added to established lymphoblastoid lines 
which contain the EBV genome but do not produce mature virus particles, an 
intra-cellular antigen complex appears. (Uenle et_ al_., 1970) This antigen 
has been termed "early antigen" (EA) since cellular DNA synthesis is not 
required for its induction. (Gergely et al., 1971) Since the superinfected 
cells do not become virus producers, the superinfection is also abortive. 
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The correlate of HA in vivo is unclear; however, high titers of antibody to 
HA are regularly found in the sera of patients with acute EBV infections or 
EBV-associated tumors such as Burkitt’s lymphoma and nasopharyngeal carcinoma. 
(Horwitz et al_. , 1975). 
The events leading to lymphocyte immortalization are poorly understood. 
Research has been hampered by the inability to identify a subpopulation of 
cells uniformly susceptible to EBV-induced transformation. Immortalization 
has been carried out on a variety of human leukocyte populations including 
leukocytes of umbilical cord, infant, and adult blood, fetal spleen, lymph 
node, and thymus. (reviewed by Miller, 1971). The calculated fraction of 
cells immortalized by F.BV, known as the efficiency of transformation, varies 
in different populations from approximately 0.0003 in adult cells to 0.03 in 
umbilical cord cells. (Henderson et al_. , 1977a). 
Evidence from several studies suggests that the susceptible target lympho¬ 
cyte in vitro bears a specific EBV receptor as well as the complement receptor 
and surface immunoglobulin which are the characteristic markers of the bone 
marrow-derived lymphocytes (B-cells) Jondal et al., 1973; Pattengale et aj., 
1974; Greaves £t a_l., 1975; Robinson et al., 1977 ). Tn contrast, thymus 
dependent lymphocytes (T-cells) with sheep red blood cell receptors lack the 
EBV receptor and are not immortalized. 
The purpose of this study was to explore the feasibility of using 
chronic lymphocytic leukemia (CLL) cells as a relatively uniform poulation of 
target cells for immortalization. CLL is a lymphoproliferative disorder 
characterized by the accumulation of large numbers of small, mature-appearing, 
functionally abnormal lymphocytes usually bearing the surface immunoglobulin 
and complement receptor markers of B-lymphocytes. (reviewed by Astaldi et al., 
1975). (CLL with a T-lymphocvte predominance has been described but will 
not be discussed further here. (Brouet et al., 1975) Studies of surface 
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immunoglobulins on the neoplastic cells have demonstrated that CLL results 
from a monoclonal proliferation (Aisenberg ejt_ al_. , 1973; see below). 
Theoretically, therefore, in a given patient the CLL cells might be uniformly 
susceptible to EBV infection. 
As will be reviewed in further detail below, the CLL cell is abnormal 
with altered ultrastructure, metabolism, and response to mitogenic agents. 
The effect of EBV on the CLL cell, however, has scarcely been documented in 
the literature. It is unclear whether the CLL cell can be immortalized. 
Chang et al.,(1976) in a study on EBV-induced transformation in various cell 
populations, examined lymphocytes from four CLL patients. Transformation 
frequency was extremely low (<10 ^), and the cellular origin (i.e. leukemia 
vs. normal lymphocytes) of the rare transformants he obtained was unknown. 
In a brief discussion note, Gergelv ct_ al. (1974) claimed that they have 
observed EBV stimulation of DNA synthesis and immortalization of CLL lympho¬ 
cytes. However, their data have never been published or corroborated. 
In preliminary experiments in this laboratory, Robinson, using the 
DNA stimulation assay, noted that EBV stimulated DNA synthesis in lymphocytes 
from one of two CLL patients (unpublished). This result suggested that this 
assay might be a useful tool to evaluate the susceptibility of CLL cells to 
EBV infection as it had been for cord and adult cells (see review below). 
An advantage of this method is its speed compared to the conventional morpho¬ 
logic assay for immortalization. 
With adult cells, in contrast to immunologically naive cord cells, it is 
necessary to distinguish the stimulation of DNA synthesis caused by EBV trans¬ 
formation from that resulting from an anamnestic response to antigen by 
lymphocytes of EBV-immune individuals. This latter response is transient 
and is induced by EBV preparations without immortalizing activity, e.g_. , 
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ultraviolet light irradiated EBV. 
In summary, an attempt was made in this study to determine whether CLL 
cells were capable of undergoing stimulation of DNA synthesis and immortali¬ 
zation by EBV. During the study, the stimulation data suggested that 
several patients were immune to EBV. To confirm this hypothesis, EBV specific 
antibody titers were performed. Unexpectedly, high titers of antibody to the 
early antigen of EBV, consistent with ongoing infection with EBV, were found. 
The significance of these titers and the possible relation to the clinical 
disease are discussed. Prior to the presentation of the data, the stimu¬ 
lation assay, EBV-specific antigens and antibodies, and the nature of the 
CLL cell will be briefly reviewed. 
EBV Stimulation of Cellular DNA Synthesis 
In 1971, Gerber and Hoyer demonstrated that EBV infection of normal human 
leukocytes induces cellular DNA synthesis. Leukocytes from EBV sero-negative 
adults were inoculated with EBV with demonstrated immortalizing activity and 
were pulsed with tritiated thymidine ([%] Tdr) at various times thereafter. 
DNA synthesis was measured by the incorporation of the isotope into acid- 
insoluble material. An increase in -VlTdr incorporation in inoculated 
cultures compared to controls was detectable three days after virus inocu¬ 
lation and a progressive increase in ^Iltdr incorporation was observed over 
the following nine days. Infected cells showed definite morphologic 
evidence of immortalization about a week after DNA stimulation was seen. 
Both DNA stimulating and immortalizing activities of the virus were elimi¬ 
nated by heat or ultraviolet radiation. 
The density of the labelled DNA on a cesium chloride gradient was the 
same as that of cellular DNA rather than of EBV-DNA implying that the virally 
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stimulated DNA was predominantly cellular. (Gerber et_ aL , 1971; Henderson 
et al., 1977b) . 
Using cord blood leukocytes, Robinson and Miller (1975), demonstrated 
that the stimulation of DNA synthesis by EBV could be used as an assay for 
virus, since the rate of ^H-Tdr incorporation in infected cells was quanti¬ 
tatively related to the initial virus inoculum. Stimulation of DNA 
synthesis by EBV was eliminated by neutralizing antibody or by exposure 
of virus to ultraviolet irradiation. Robinson et_ al. ,(1977) recently showed 
that only B-lymphocytes with complement receptors are susceptible to trans¬ 
formation by EBV. In addition, when T-cel1-depleted lymphocytes are fractio¬ 
nated on the basis of size, the homogeneously small lymphocytes found in the 
b) 
peak fractions are transformed by EBV. (Henderson et_ al., 1977 Since 
these cells have a very low level of spontaneous DNA synthesis, it appears 
that resting B-lymphocytes are preferentially transformed by EBV. Further¬ 
more, the subpopulation in which EBV stimulates DNA synthesis is the same 
which is transformed (Robinson et al., 1978). 
Gerber also demonstrated that the stimulation assay could be used 
to detect cell-mediated immunity to EBV antigens. (Gerber and Lucas, 1972^°) 
He examined EBV stimulation of DNA synthesis in lymphocytes from EBV sero¬ 
positive donors (complement-fixing antibody titers of 1:8 to 1:512), and 
found that increased ^II-Tdr incorporation occurred after inoculation with 
either active or UV-inactivated virus (UV-EBV). This finding suggested an 
immunologic response of sensitized lymphocytes to specific antigen. The 
time course of UV-EBV stimulation differed from that caused by active virus 
in cells from non-immune donors. UV-EBV induced synthesis appeared on days 
3 to 4 and increased rapidly, reaching a peak on day 7 with a sharp decline 
thereafter. The antigenic stimulatory effect of UV-EBV was not inhibited ny 
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preincubation of the antigen with EBV antibody whereas the immortalizing 
activity of live virus was. Recently, Gergely et a_l. (1977) showed that 
purified T-cells from sero-positive but not seronegative individuals were 
stimulated by EBV. 
In summary, EBV stimulates cellular DNA synthesis in human leukocytes 
by two mechanisms: (1) infection of B-lymphocytes, and (2) antigenic 
stimulation of sensitized T-lymphocytes. The first reaction requires 
biologically active virus and is independent of the EBV-antibody status of 
the cell donors. In the second mechanism, only lymphocytes from EBV sero- 
po sitive donors are reactive- Virus which has been inactivated by 
exposure to UV-light or neutralized by antibody remains stimulatory. 
Furthermore, antigenic stimulation is transient while infection induces a 
permanent stimulation. 
EBV Specific Antigens and Antibodies 
Since prior immunity to EBV serves to distinguish the mechanisms of 
in vitro viral stimulation of DNA synthesis, EBV specific antibodies were 
measured in the patients in this study. Four major groups of EBV-specific 
antigens have been described. (Henle and Henle, 1975; Miller, 1975). This 
section will review the antigen-antibody systems of clinical significance 
and the presence of EBV antibody in CLL patients. 
Viral capsid antigen (VCA) is an intracellular antigen detected only in 
those cells which are producing EBV. VCA is not usually found in fresh 
tissue specimens from Burkitt lymphoma or infectious mononucleosis (IM) 
but appears in cells of lymphoblastoid lines which produce virus (Henle and 
Henle, 1966). The source of antigen in vivo for stimulation of antibody 
synthesis is not known but is postulated to derive from a few productively 
infected cells which degenerate and release their contents. (Henle and 
Henle, 1975). 
6 
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Although IgM antibodies to VCA have been described (Schmitz and Scherer 
1972), only IgG anti-VCA antibodies,detected by indirect immunofluorescence 
are routinely measured for epidemiologic studies. In infectious mononu¬ 
cleosis, anti-VCA antibodies with titers usually ranging from 1:80 to 1:320 
are found early in the disease. These levels decline over approximately 
six months to titers of 1:20 to 1:160 and appear to persist for life. No 
correlation exists between the peak titer of antibody and the clinical 
severity of the disease. (Niederman et_ al_. , 1968). 
Anti-VCA antibodies are present in patients with Rurkitt’s lymphoma 
(BL) and nasopharyngeal carcinoma (NPC). Although there is no significant 
difference in prevalence of these antibodies in patients and control groups 
mean 
in the endemic area, the majority of patients will have geometric,titers of 
anti-VCA 8 to 10 times higher than that of controls (Henle et_ al_., 1969, 1973a^. 
In NPC, the titer of anti-VCA correlates with advancing disease and declines 
with successful eradication of the tumor. (Henle et al., 1973n). 
Epstein-Barr nuclear antigen (EBNA) is detected in all F.BV-genome 
containing lymphoblastoid cells by the method of anticomplement immunofluores¬ 
cence. (Reedman and Klein, 1973). Unlike VCA, EBNA is found in vivo and 
has been described in cells from BL, NPC, and experimental EBV-induced lymphoma 
of marmosets. Presence of the antigen does not depend on the production of 
virus. (Lindahl e_t al_. , 1974). 
Anti-EBNA antibodies arise after all primary EBV infections and persist 
for life, (Miller, 1975). However, determination of anti-EBNA levels offers 
no advantage over anti-VCA levels. 
Early antigen (EA), as noted in the introduction is an intracellular 
antigen appearing after superinfection by certain EBV strains of lymphoblastoid 
lines which contain the EBV genome but do not produce virus, e.g., Raji and 
RPMI 64-10. (Henle et al., 1970). EA can also be induced in the same lines 
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by halogenated pyrimidines such as 5 iododeoxyuridine and bromodeoxyuridine 
(Gerber a -- T ucas, 1972a). 
EA is detected by indirect immunofluorescence with sera empirically 
shown to be reactive in superinfected cells. The antigen is presumed to 
exist in virus producer cell lines but cannot be specifically identified 
since these cells also contain VCA. No sera are available which have anti- 
EA activity but lack anti-VCA antibody. (The location of EA in. vivo is not 
known.) The denies have described two components of EA: (1) the diffuse 
component (D) which is cytoplasmic and intranuclear, and resists methanol 
fixation; (2) the restricted component (R) which is present only in the 
cytoplasm and is methanol labile. (Ilenle et_ al., 1971a) . The two com¬ 
ponents are difficult to distinguish from one another since they can exist 
in the same cell. 
Antibodies to EA are associated with IM, BL, and NPC. In IM, appro- 
imately 70 percent of patients develop anti-EA titers of 1:10 to 1:320. 
The peak titer of anti-EA occurs 2 to 4 weeks after anti-VCA. Unlike anti- 
VCA and anti-EBNA, anti-EA is said to disappear within several months of 
primary infection and is therefore useful as an indicator of ongoing or recent 
infection. (Henle et a1. , (1971^). The denies have suggested that patients 
with high titers of anti-EA (?1:80) more often have clinically severe 
disease requring steroid therapy than do patients with lower titers. Since 
EA is an intracellular antigen, the denies propose that high titers of anti- 
EA result from greater cellular necrosis. 
In BL as well, approximately 70 percent of patients have anti-EA. Hightiteis oi 
correlate with poor prognosis. All patients with a short course of six months 
between diagnosis and death had titers of anti-EA greater than 1:160 whereas 

only 44 percent of patients surviving greater than 2 years had equally high 
titers. (Henle et al., 1969 ). In treated patients in remission, anti-EA 
declined and even disappeared. Similarly in NPC, anti-EA is present with 
the height of the titer correlating with stage of the disease and prognosis. 
As with anti-VCA, the titer of anti-EA antibodies declines with eradica 
tion of the tumor (Henle et a_l., 1973^). 
As a rule, the anti-EA present in IM and NPC is usually anti-D whereas 
anti-R is the predominant anti-EA antibody in BL. Since the biologic 
differences between the diffuse and restricted antigens are not known, the 
reason for disease specificity is matter of speculation. The Henles have 
proposed that anti-D might be related to lymph node involvement based on the 
observation that lymphadenopathy is more prominent in IM and advanced NPC 
than in BL. (Henle et al., 1973b). 
In general, anti-EA is rare in control populations (3 to 5%) and, if 
present, is of low titer (4,1:25). (Henle and Henle, 1973). Whether there 
is a correlation between persistent anti-EA and the prolonged oropharyngeal 
excretion of virus known to occur in some IM patients has not been investi¬ 
gated (Miller, Niederman, et al., 1973). 
Other EBV antigen-antibody systems which have been described include 
membrane antigen (MA) which is present on living Burkitt lymphoma cells. 
Anti-MA is analogous to anti-VCA in its clinical occurrence. (Gunven et_ al. 
1974). Complement fixing antibodies to soluble EBV antigens are comparable 
to anti-EBNA. Of all the EBV antibodies extensively studied, anti-EA has a 
special significance since it appears to correlate with clinical course and 
prognosis. 
EBV-Specific Antibodies in CEL 
Following reports of the association of EBV with IM and BL, antibodies 
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to EBV were sought in other lymphoproliferative diseases including CLL. 
Four major studies have been published. Johansson and his colleagues (1971) 
compared anti-VCA titers in 96 sera from 59 CLL patients with sera from 47 
normal controls. The geometric mean titer in the CLL sera was 1:79 com¬ 
pared to 1:43 in the control sera, although the percentage of CLL sera with 
high titers, i.e, ,greater than 1:160, exceeded that of controls, 45% to 17%. 
Subdivision of the CLL sera by the patients' presenting symptoms, gamma¬ 
globulin levels, and survival failed to correlate with titer. Sera from 
patients with higher peripheral leukocyte counts tended to have higher 
titers. 
The study is flawed, since it is unclear which patients furnished 
multiple serum specimens. If samples were obtained more frequently from 
patients with high titered antibodies, the mean titers would be misleadingly 
elevated. 
In another study on anti-VCA titers in CLL, Levine et al., (1971) 
found significantly higher titers (geometric mean titer = 1:444) in 34 
patients than in controls (mean 1:90). There was no correlation between 
titer and lymphocyte count or gamma globulin level. Insufficient clinical 
information is presented to determine how these patients differed from 
Johansson's series The reason for the discrepancy in titers is therefore not 
clear. 
In a more recent study (Hesse et al., 1973) of 14 CLL patients, the 
mean titer of anti-VCA (1:195) and anti-EA (1:12) were significantly 
elevated compared to control titers, 1:45 and 1:3, respectively. A hypo¬ 
thesis that the titers of antibody might correlate with impaired delayed 
hypersensitivity was not corroborated. Two patients had high titers of 
anti-EA (1:160 and 1:2560) but their clinical courses were not described. 
10 
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In the largest series to date, the Ilenles examined sera from 235 patients 
with CLL (Henle and Henle, 1973). Ninety-three percent had anti-VCA titers 
greater than 1:10 (mean titer, 1:110) compared to 91% of "old adults" 
(mean titer 1:51). Forty-six percent of the CLL patients had anti-EA (mean 
titer 1:46) compared to 5% of controls (mean titer 1:25). Clinical data on 
these patients were not presented. 
There have been no satisfactory explanations why anti-VCA and anti-EA 
are elevated in CLL (or in Hodgkin's disease or lymphomas where increases 
are also observed). There is no evidence that EBV is causally related to 
CLL. The denies have proposed that defective cellular immunity associated 
with malignancy somehow disrupts the balance between cellular and humoral 
immunity thereby permitting exacerbation of a persistent EBV infection and 
therefore increased anti-EBV antibodies. 
Clinical Description of CLL 
CLL is a chronic disorder characterized by the accumulation in the 
lymphoid organs, bone marrow, and peripheral blood of long-lived, functionally 
abnormal cells resembling small mature lymphocytes. (Reviewed by Durant, 1972) 
Afflicting older people, CLL is most common after the age of 50, and occurs 
slightly more frequently in males (ratio 3:2). 
Certain manifestations of the disease are a direct consequence of the 
infiltration of organs by leukemic cells. Lymphadenopathy, splenomegaly, 
and hepatomegaly commonly occur. The skin (leukemia cutis) and gastrointes¬ 
tinal tract may be involved. Bulky disease produces secondary complications, 
£.g_., mediastinal adenopathy may cause partial bronchial occlusion or 
superior vena caval syndrome. In advanced cases, replacement of the marrow 
with CLL cells ("packed marrow") interfe^3with other hematopoietic precursors 
11 
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and leads to anemia, thrombocytopenia, and neutropenia. 
Additional findings are secondary to the disordered B-cell function of 
the CLL cell. Hypogammaglobulinemia resulting in an increased susceptibil¬ 
ity to infection is present in advanced CLL. Production of abnormal anti¬ 
bodies as demonstrated by the increased incidence of Coombs positive hemo¬ 
lytic anemia, cold agglutinins, and monoclonal gammapathies can also occur. 
Diagnosis of the disease is based on the findings of a sustained lympho 
7 
cytosis greater than 15,000/mm in the peripheral blood and of greater than 
30% of the nucleated white cells in the marrow. In cases of doubt, for 
example where the absolute lymphocytosis is less than 15,000, clinical 
follow-up for development of increasing adenopathy, splenomegaly and bone 
marrow infiltration can confirm the suspected diagnosis. 
CLL displays a wide variety of activity. Some patients will have a pro 
longed indolent course (> 10 years) not requiring therapy. Other patients 
will have more aggressive disease. In patients with active disease, the 
response to therapy is variable. Research on clinical staging systems which 
categorize patients according to the presence of adenopathy, splenomegaly, 
anemia, and thrombocytopenia, has demonstrated that median survival time is 
significantly shorter in patients who present with or develop anemia and/or 
thrombocytopenia (19 months) than in patients with lymphocytosis with or 
without adenopathy (100 to greater than 150 months). (Rai, et al., 1975; 
Binet, e_t aj_* , 1977). 
Current thinking on the nosology of CLL has emphasized that the term 
does not encompass a single disease entity but rather a spectrum of disease 
of morphologic diversity. (Kass, 1976). In addition there has been 
speculation that the lymphocytic leukemias and lymphomas are different 
clinical expressions of the same neoplastic process. (Jaffe, 1976). Thus, 
12 
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similar to the classification system for the lymphocytic lymphomas based 
on the stage of differentiation of the neoplastic cell, CLL may be sub¬ 
divided into categories of well- to poorly-differentiated disease. This 
latter category, also termed chronic lymphosarcoma cell leukemia (CLSL) is 
characterized by the predominance of large atypical lymphocytes with clefted 
nuclei, prominent nucleoli, reticulated nuclear pattern and scant to abundant 
cytoplasm. (Schwartz et a_1. , 1965). The clinical significance of this 
subdivision is that patients with CLSL are reported to have a poorer 
response to therapy, more aggressive disease, and decreased survival. 
(Schnitzer et al., 1970; Zacharski et al., 1969). Recent studies, however, 
have contradicted this finding, and the issue remains unresolved. (Peterson 
et al., 1975; Knospe et aj_. , 1977). 
In this study, cells were obtained from one patient carrying a diagnosis 
of CLSL in order to compare whether the stage of differentiation influenced 
the susceptibility to EBV stimulation and immortalization. 
The CLL Cel1 
Ease of obtaining large numbers of CLL cells from peripheral blood has 
facilitated extensive study of the structure and function of this abnormal 
cell population. (review articles: Perera et al. , 1974; Theml et al., 1977). 
The poorly differentiated lymphocytic leukemia cell, the lymphosarcoma cell, 
has not been as thoroughly characterized. (Ouaglino et al., 1964; Knospe 
et al., 1977). In this section, the chief differences between the normal 
lymphocyte and we 11 differentiated leukemia cell, and the evidence for 
monoclonality will be reviewed. 
Structural and Metabolic Differences 
The tendency for CLL cells to form smudge cells or damaged cells on 
13 
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routine smears is an easily observed consequence of the abnormal structure 
of the CLL cell membrane. By electron microscopy, the membrane is thicker 
than in normal lymphocytes. (Catovsky et al_. , 1971). Decreased membrane 
fluidity and turnover of constituents have also been observed. (Holt et ajL , 
1972; Lewis et al., 1976). Ultrastructura1 studies have shown a predominance 
of smooth nuclei, small mitochondria, and decreased amounts of cytoplasm 
which correlate with diminished metabolic activity. (Schrek, 1972). 
Glycogen metabolism is abnormal: excessive amounts of intracellular 
glycogen accumulate. Turnover is diminished presumably because of a relative 
deficiency of glycolytic enzymes. (Brody et al., 1969). The number of 
lysosomes and the level of lysosomal enzymes are diminished. (Douglas, 1972). 
The activity of DNA synthetic and catabolic enzymes is diminished. (Loeb 
et al., 1973^mbr°giet al., 1977). The CAMP of the CLL cell level is low. 
(Astaldi et_ al_., 1975). The overall significance of any of these abnormali 
ties is a matter of speculation. 
Surface Markers and the Origin of the CLL Cell 
As noted in the introduction, the conclusion that the neoplastic cell 
in CLL is commonly of B-lymphocyte origin is based on the evidence from 
multiple studies that in most cases the predominant lymphocyte bears membrane- 
bound immunoglobulin, the sine qua non of the B cell. (reviewed by Astaldi 
et aT_., 1975). Rare cases have been described in which the predominant cell 
type is a T cell which forms sheep red blood cell rosettes (E-rosettes) and 
is killed by T-lymphocyte specific antiserum. Even more unusual are two cases 
in which lymphocytes were found with both T and B markers. (Polliack et al., 
1973; Shevach et al., 1973). 
In the normal adult, approximately 70 to 80 per cent of the peripheral 
lymphocyte population can be identified as of T-cell origin on the basis of 
14 

ability to form E-rosettes. Another five to 15 percent, identified as B-cells, 
have surface immunoglobulin and usually receptors for complement and the Fc 
moiety of IgG. The remaining 5 to 15 percent of the lymphocyte population 
have some other constellation of markers and remain largely unclassified. 
In contrast, in one series, typical of CLL patients, the percentage of E-rosette 
forming cells ranged from 3 to 31% with the majority of patients having less 
than 15% T-cells, whereas the percentage of cells with surface immunoglobulin 
ranged from 66 to 95%. (Davis, 1976). 
The distribution of B-cell surface markers is not constant from one CLL 
patient to another. Dissociation of markers occurs in which, the markers 
on the leukemic lymphocytes of one patient will differ from those on cells 
of another patient. This variation has been postulated to represent differ¬ 
ences in the maturity of the neoplastic cell population in different patients 
since it is known that the constellation of surface markers changes as the 
B-lymphocyte matures. (Gelfand et al., 1974). 
Monoclonality of the Leukemic B-Lymphocyte 
Evidence that the predominance of neoplastic B-lvmphocytes in CLL results 
from a monoclonal proliferation is derived from characterization of the 
surface immunoglobulins by fluorescence microscopy. In a given CLL a 
patient, the lymphocyte surface immunoglobulin is predominantly of one heavy 
chain type (mu or gamma) and of one light chain type (kappa or lambda). 
(Aisenberg et^ ad_. , 1973). In patients in which the predominant immuno¬ 
globulin is IgG, there is restriction to one IgG subclass and allotype. 
(Froland £t al., 1972). Recently with the development of anti-TgD reagent, 
it has been shown that many CLL B-cells bear both surface IgM and IgD. The 
immunoglobulin idiotype has been shown to be identical for the IgM and IgD 
on different cells suggesting that all the cells arise from one clone. 
(Salsano et al., 1974.) 
15 
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Mitogen Responsiveness 
Functional abnormalities of CLL cells noted in vitro include decreased 
responsiveness to various mitogens, impaired cytotoxic activity, and diminished 
and deranged immunoglobulin secretion. (Perera et al., 1974; Mellstedt 
et al., 1974; Maino e_t ad., 1977). In reference to the present investigation, 
the decreased response to mitogens is most pertinent since EBV stimulation 
causes DNA synthesis and morphologic change as do the plant mitogens. Too 
little is known about the subcellular mechanisms of EBV stimulation to make 
comparisons with proposed mechanisms of mitogen stimulation. However deter¬ 
mination of which lymphocyte population is abnormal in CLL might illuminate 
the nature of the EBV response. 
Phytohemagglutinin (PHA), a lectin derived from kidney beans, stimulates 
DNA synthesis and causes morphologic changes selectively in T-lymphocytes. 
(Greaves et al., 1974). in a mixed population of normal human lymphocytes, 
PHA causes stimulation of DNA synthesis beginning on day 2, peaking on day 3, 
and steadily declining to baseline over the next seven days. 
Pokeweed mitogen (PM), stimulates normal B-lymphocytes to synthesize 
DNA, proliferate, and differentiate into immunoglobulin secreting cells. 
(Janossy et_ a_l_., 1975). T-cell participation is required, and the T-cells 
themselves are stimulated. 
Numerous studies have shown that in lymphocytes from CLL patients, the 
DNA synthetic response to these mitogens is diminished in magnitude and 
delayed in onset. (Rubin et al., 1969; Abell et al., 1970; Smith et al., 1972). 
However, studies performed prior to 1971 failed to distinguish the contri¬ 
butions made by T and B cell subpopulations. Wybran hypothesized that the 
delay and diminution of the synthetic response to PHA were a consequence of 
dilution by non-responding leukemic cells of a small but normally reactive 
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T-cell population. (Wybran e_t al., 1973), By the method of E-rosette centri¬ 
fugation, a T-lymphocyte fraction was isolated from the peripheral blood of 
CLL patients. In these cells, the PHA response was normal. In contrast, the 
remaining T-depleted population, consisting largely of immunoglobulin-bearing 
cells, had virtually no response to PHA. Although these results do not prove 
that all the T-cells in CLL are normally responsive, the data did show that 
a normally reactive subpopulation does exist. Controversy remains, however, 
with some investigators believing that the T-cells are abnormal as well. 
(Utsinger, 1975; Schultz et ad. , 1976). Wybran applied the same experimental 
model to PWM responsiveness and found that the T-cells from CLL patients 
were stimulated although mixed or T-cell depleted populations were not. 
This data together with similar work by others (Smith et_ a_l. , 1972; Catovskv 
et_ al., 1972; MeUstedt et_ aj_, 1974) point to a defect in B-cell responsiveness 
in CLL. Since the failure to respond to PWM could also be a result of in¬ 
sufficient numbers of helper T-cells, experiments are now in progress investi¬ 
gating the effect of different normal T-cell subpopulations on CLL cell 
mitgen responsiveness (Moino et_ ad. , 1977). 
In summary, current evidence suggests that in CLL B-lymphocyte function 
is impaired while certain T-lymphocyte functions appear to be normal. 
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MATERIALS AND METHODS 
Lymphocyte and Serum Donors 
Patients with a diagnosis of CLL or chronic lymphosarcoma leukemia 
served as donors. With the exception of one inpatient, all patients 
were selected at random from the population of CLL patients followed in the 
Hematology Outpatient Clinic. Healthy adults served as donors of normal 
lymphocytes and sera. Informed consent was obtained with a permit approved 
by the Human Investigations Committee (see appendix). 
Medium 
The medium for all leukocyte cultures and cell lines was RPMI 1640 
(Grand Island Biological Co.) supplemented with heat inactivated fetal calf 
serum (20% v/v), penicillin (50U/ml), streptomycin (50 fug/ml) , and ampho¬ 
tericin B (lug/ml). Cells were washed with Hanks Balanced Salt Solution 
(HBSS) unless otherwise stated. 
Isolation of Lymphocytes 
Lymphocytes were separated from heparinized venous blood on a Ficoll- 
Hypaque gradient using a modification of the method of Bovum (Boyum, 1968). 
Blood was obtained by venipuncture in sterile heparinized glass tubes. 
Routine smears were made, stained with Giemsa, and a differential count 
performed. Following centrifugation of the sample at 400 xg for 10 minutes, 
the plasma was removed and stored at -20 C for later antibody studies. 
To isolate the lymphocytes, five ml of buffy coat and packed cells 
were diluted with 15 ml of HBSS and then layered on 10 ml of Ficol1-Hypaque. 
The gradient was centrifuged at 400 xg at room temperature for 40 minutes. 
The interface cell layer was carefully removed by pipette, resuspended in 
HBSS, and washed twice. The cells were resuspended in complete medium and 
counted in a hemocytometer. The cell concentration was adjusted to 2xl0^/ml. 
18 

Ficoll-Hypaque separation resulted in a greater than 95% pure mononuclear 
cell suspension. 
The cells were placed in Corning plastic culture flasks, gassed with 
5% C09, and incubated overnight at 36 C. 
Lymphocyte Markers 
A. Assay for lymphocytes binding sheep red blood cells (E-Rosettes). 
The percentage of T cells was measured by enumerating the proportion 
of lymphocytes with receptors for neuraminidase treated sheep red blood cells 
(SRBC)Weiner et_ a_l., 1973). One ml of a 5% suspension of washed SRBC in 
HBSS mixed with 0.05 ml Neuraminidase (500 U/ml; Calbiochem) and incubated 
for one hour in a 37 C water bath. The cells were then washed x 3 with 
HBSS and resuspended in one ml HBSS. 
Lymphocytes (0.1 ml containing 2 x 10^ cells) were mixed with 0.05 ml 
of SRBC and centrifuged at 200 xg for 10 minutes at room te^mperature. The 
pellet was left undisturbed at 4 C for one hour, then gently resuspended and 
examined under the microscope. Each sample was tested in duplicate. At 
least 200 cells were observed for rosette formation; a E-rosette was de¬ 
fined at a lymphocyte to which three or more SRBC were attached. 
B. Assay for complement-receptor bearing lymphocytes (EAC rosettes). 
The percentage of B cells was estimated by measuring the percentage 
of lymphocytes with complement receptors. (Bianco et al., 1970). One ml of 
5% SRBC was mixed with an equal volume of 19S-rabbit anti-SRBC. The mixture 
was incubated for 30 minutes at 37 C. The cells were washed twice in Gelatin- 
Veronal Buffer (GVB) and resuspended in 1 ml GVB. An equal volume of the 
complement source (mouse serum diluted 1:10 with GVB) was added and the 
mixture was incubated at 37 C for 30 minutes. The cells were again washed 
twice and resuspended in 1 ml GVB. 
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To make the EAC rosettes, 0.1 ml of lymphocyte suspension was mixed with 
0.05 of 1% EAC and incubated for 30 minutes at 37 C. The suspension was 
gently resuspended and examined in a hemocytometer for rosette formation. 
EAC rosettes were defined as a cellsbinding 3 or more treated SRBC. 
Isolation of Lymphocyte Subpopulations 
T-cell enriched (T ) and T-cell depleted (T-) lymphocyte fractions 
were prepared from the separated lymphocytes by mixing the cells with SRBC 
to from E rosettes and centrifuging the mixture on a Ficol1-Hypaque gradient. 
Rosette forming T-cells with SRBC receptors pelleted through the gradient 
whereas non-rosette forming cells (non-T) remained at the Ficol1-medium 
interface. (Wahl et al., 1976). 10 ml of a 1% suspension of washed SRBC 
were mixed with an equal volume of lymphocytes at a concentration of 1 to 
2 x 10 cells/ml. The mixture was centrifuged at 200 xg for 10 minutes at 
room temperature and then placed at 4C for 60 minutes. The mixture was 
gently agitated, layered on 10 ml of Ficol 1-liypaque, and centrifuged for 30 
minutes at 400 xg at room temperature. Following centrifugation, the inter¬ 
face cells (T-) were collected, washed twice, and resuspended in complete 
medium. The pelleted cells (T^+ SRBC) were washed once and resuspended in 
5 ml BBSS. To lyse the SRBC, 10 ml of a solution contuining 155 mM NHuCL, 
10 mM KHCOj and 0.1 mM EDTA (pH 7.4) were added. The cells were immediately 
pelleted at 4°C, washed twice and resuspended in medium. Lymphocyte markers 
(E, EAC) were tested on the fractionated cells. 
Preparation of Virus Stocks (Robinson and Miller, 1975). 
The B95-8 strain of EBV was prepared from a marmoset cell lines (B95-8) 
originally immortalized with EBV from a case of transfusion-induced infectious 
mononucleosis. (Miller and Lipman, 1973). The infected marmoset cells 
were seeded at a 3 x 10° cells/ml and incubated at 36 C for 7 days. Super¬ 
natant culture fluid was then centrifuged to remove cells, frozen and thawed 
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three times and passed through a 0.8 pm membrane filter (Millipore Corp.). 
Tnfectivity of the stock was 4.5 log.^ 50% transforming doses (TD ) per 
0.1 ml as assayed by the ability of virus dilutions to transform umbilical 
cord cells. The stocks contained approximately 10 to 10' physical parti¬ 
cles/ml as determined by virus particle counts of negatively stained 
hanging drop preparations. (Miller and Linman, 1973^). ftocks were 
stored at -70 C. 
As a control for non-specific cellular metabolites which might stimulate 
cellular DNA synthesis, a virus free supernatant was prepared. Super¬ 
natant culture fluid from Raji cells, a non-producer lymphoblastoid line 
derived from a Burkitt lymphoma patient, was frozen and thawed three times 
and filtered. This fluid lacks the ability to transform leukocvtes and 
was shown in preliminary experiments to have no stimulating activity. 
Preparation of UV irradiated EBV (UV-EBV). 
One milliter aliouots o-o virus stock were placed in 60 mm petri dishes. 
UV light was delivered by a 15 watt GE 15T8 low-pressure mercurv germicidal 
lamp. UV dose rate was 600 ergs/mm^ per min for 10 minutes. This dose has 
been shown to eliminate the abilitv of EBV to stimulate DNA synthesis in 
human cord leukocytes. (Robinson and Miller, 1975). 
Phytohemagglutinin 
Phytohemagglutinin, (PHA, Difco Laboratories), a selective T cell 
mitogen, was prepared as a stock solution of 1 mg/ml and used in lymphocyte 
cultures at varying concentrations of 2.8 to 50 up/ml. 
Lymphocyte cultures 
Lymphocyte cultures were set Tip in accordance with one of two methods. In 
method one, a single 25 ml Corning culture flask was used for each test 
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parameter. For each 4 ml of cell suspension (2 x 10 cells/ml), one ml of 
supplemented medium and one ml oF test stock (ERV, UV-EBV, pHA, or medium 
control) were added. The final volume was either 6 or 9 mis with a final 
cell densitv of 1.3x10 /ml. The cultures were passed with 5% apd in¬ 
cubated at 36 C. The medium was partially changed weekly one or two days 
before the [3H]Tdr pulse. 
In method two the lymphocyte suspension was distributed to sterile 
stoppered tubes (13x100 mm) in 0.4 ml aliquots. 0.1 ml oF supplemented 
medium plus 0.1 ml oF test stock were added to make a total volume of 0.6 ml. 
Multiple tubes were set up for each parameter such that each [3H]Tdr pulse 
could be performed in duplicate on each test day. 
After several initial experiments, method 1 was used exclusively since 
it was less time-consuming and minimized pipetting erros. 
Pulse Assay for DNA Synthesis (Pobinson and Miller, 1975) 
[3H]Tdr incorporation into acid-insoluble material was measured in control 
and ERV, UV-EBV, and PHA inoculated cultures. 
When leukocytes were cultured bv method 1, 0.6 ml aliquots of cell 
suspension were removed from the culture flasks and placed in 13x100 mm 
stoppered tubes. 0.5 ml of [3H]Tdr (specific activity 6.7 Ci/mm; New Enpland 
Nuclear) at a concentration of 5uci/ml was added to each tube. The Final 
concentration of the isotope was 2.3uci/ml. The suspension was then 
incubated for 60 minutes in a 37 C.water bath. The reaction was stopped 
by the addition of 4 ml of cold HBSS, and the suspension was centrifuged 
at 200 xg for 10 minutes at 5 C. The supernatant was removed and the 
pellet was resuspended in 3 ml of 5% trichloracetic acid (wt/vol) in water. 
The tubes were kept at 4°C for a minimum of 20 minutes. 
The precipitates were collected on 2.5 cm membrane filters (millipore 
Corp., type HA, 0.45 urn) and washed twice with distilled water. The filters 
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were placed in vials, dried, and 4 ml of Fconofluor (New England Nuclear) 
was added. Incorporated radiactivity was determined in a liquid scintil¬ 
lation counter. 
For leukocytes cultured ini tiallv in tubes (method 2), the 0.5 ml 
of isotope solution was added directly and the remainder of the pulse 
carried out as above. 
Immortalization (transformation) 
All lymphocyte cultures, whether ERV inoculated or control, were observed 
weekly for evidence of immortalization (or transformation) into lympho- 
blastoid lines. Cultures were evaluated for the following: 
1. Change of morphology of cells from small, round cells to 
larger ameboid cells with pseudopodia; 
2. Acid production as demonstrated by a color change of the 
pH indicator of the medium; 
3. Clumping of cells; 
4. Proliferation and ability o-p the culture to grow following 
subdivision. 
All viable cultures without evidence of transformation were observed for 
a minimum of six weeks. 
Fluorescent Antibody Tests ^or Antibodies to ERV Viral Capsid Antigen 
and Early Antigen 
Antibodies in patient sera to VCA and FA were measured by indirect 
fluorescent antibody tests. (Andiman and Miller, 1976). The general 
method was to prepare smears of cells containing the appropriate antigen, 
incubate with test sera of increasing dilution, and then add fluorescein 
conjugated anti-human IgC to stain cells with bound IgC. All sera were 
heat inactivated by incubation for 30 minutes at 56°C. 
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A. Preparation of VGA smear. 
Antigen smears were prepared from suspensions of an FBV-producer cel 1 
line (B95-8). 3ml at 10^ cells/ml were pelleted and the cells resuspended 
in 0.1 ml phosphate-buffered saline (PBS). The suspension was smeared on 
coverslips or glass slides, allowed to dry, and then fixed in acetone for 
10 minutes. Smears of non-producer cells (Raji or transformed umbilical 
cord leukocytes) which are VGA negative were used as controls for non¬ 
specific anti-cellular antibodies. The smears were stored at -20 C until use. 
B. Preparation of EA smears. 
"Early antigen" appears in non-producer lvmphoblastoid lines (Raji, 
64-10) following superinfection withvirus concentrates of the P J-HR1 
Burkitt cell line. Superinfection was performed by adding 3 ml of supernatant 
fluid derived from cultured P^J-HRl cells to an equal volume of Raji cells 
at a cell density of 10^ cells/ml. Four days after superinfection, the 
cells were washed, pelleted, and smeared on coverslips on slides as des¬ 
cribed above. Raji cells which had not been superinfected were used as 
negative controls. 
C. Indirect Fluorescence Antibody Test 
Sera were serially diluted ten-fold with pBS in a microtiter tray. One 
drop of serum dilution was added to each smear. Known positive and negative 
sera were used as controls. The slides were then incubated for one hour at 
37 C in a moist chamber. The slides were rinsed with cold PBS and washed 
twice for 5 minutes. One drop of fluorescein-isothiocyanate conjugated goat 
antihuman IgG (Antibodies, Inc.) diluted 1:10 with PBS was placed on each 
smear. The slides were again incubated for one hour, washed five times for 
3 minutes, and dried with a hair dryer. The coverslips were mounted with 
buffered glycerol (pH 9) on acetone cleaned slides and examined under a 
Leitz-Wetzlar indirect illuminating fluorescence microscope. 
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RESULTS 
Patients 
Eight patients (7 males, 1 female) with the diagnosis of CLL were 
entered in this study. The clinical data are summarized in Table I. Six 
patients (#1-6) had well differentiated CLL with a predominance of small, 
mature lymphocytes. Two patients (#7,8) were considered to have poorly 
differentiated CLL because of the large proportion of poorly differentiated 
lymphoblasts (20-40% of nucleated cells) present in the peripheral blood 
and bone marrow. The cells, classified as lymphosarcoma leukemia cells, 
had increased diameter, prominent nucleoli and clefted nuclei, and an 
open reticulated chromatin pattern. (Zacharski et al., 1969). 
The ages of the CLL patients ranged from 48 to 78 years old with a 
median age of 66 years. Duration of disease from presentation to entrance 
into the study ranged from less than one month to 13 years with a median 
duration of 5 years. 
According to the clinical staging system proposed by Binet et al., 
(Table I) the distribution of patients at the time of initial presentation 
was as follows: Stage 0: 2; Stage II: 2; Stage III: 3; Stage IV: 1. 
Over the period of observation at Yale, the patients' clinical courses have 
varied. Patient #5 presenting in Stage II has spontaneously improved with 
a decrease in lymphocytosis and disappearance of splenomogalv within three 
months of diagnosis. Patient #2, presenting with serendipitously discovered 
lymphocytosis in 1965, has had a very slowly progressive course, but has 
never been treated. Patients #1 and #4, each with CLL for eight years and 
evidence of disordered immunity, have had indolent disease controlled with 
chemotherapy. In contrast, patients #3 and #6 have had more active disease 
with constitutional symptoms and hypersplenism reouring chemotherapy and, 
for patient #6, splenic irradiation. 
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The two patients with CLL with poorly differentiated cells have had 
clinically aggressive disease with complications and will be discussed 
briefly. 
Patient #8, hospitalized in February, 1976, with a two month prodrome 
of night sweats, dyspnea, lethargy and 30 pound weight loss was di agnosed 
as having CLL with multifocal adenopathy and massive hepato-splenomegaly. 
The white count was 520,000/mmwith 83% lymphocytes and 14% abnormal pre¬ 
cursors. Anemia and thrombocytopenia were present. The bone marrow biopsy 
revealed hypercellularity and infiltration with lymphoid cells (40% lympho¬ 
blastic forms). Treatment with vincristine, cyclophosphamide, and predni¬ 
sone produced a drop in whit&-count to 100,000 but anemia and thrombocyto¬ 
penia persisted. Agranulocytosis developed, and the patient developed 
sepsis despite antibiotics. The white count plummeted to 17,000. On the 
30th hospital day, the patient died. Post-mortem examination revealed 
multiple fungal abscessed (Candida albicans) as well as the underlying wide¬ 
spread lymphoproliferative disease with diffusely infiltrated lymph nodes. 
Patient #7 was admitted to the hospital in May, 1976 because of asthenia 
and left upper quadrant pain. Splenomegaly and adenopathy were noted. 
*7 
The white count was 86,Oo/mm'5 with 47% lymphocytes. The marrow was infiltrated 
with lymphocytes. Prednisone therapy was begun. In November, 1976, the 
patient was hospitalized because of severe anemia and weakness. The spleen 
was palpable at the iliac crest. The white count had risen to 55,900 with 
79% lymphocytes of which more than half were large immature cells with pro¬ 
minent clefts and nucleoli. Thrombocytopenia and hypogammaglobulinemia 
were present. The diagnosis of chronic lymphosarcoma cell leukemia was 
made. A single course of vincristine and splenic radiation produced mild 
temporary improvement in the lymphocytosis and splenomegaly. However, 
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the patient was readmitted in March, 1977, for splenectomy and radiation of a 
retropharyngeal mass, believed to be a lymph node but not biopsied. Since 
then the white count has continued to climb and the patient has had constitu¬ 
tional symptoms. Chlorambucil therapy has produced no response. 
Enumeration of T and B Lymphocytes (Table II) 
The percentage of EAC-rosette-forming lymphocytes was elevated in all 
patients and ranged from 67 to 91.5 percent compared to the normal range 
of 10 to 30 percent reported in the literature. (Astaldi et al,, 1975). 
The percentage of E-rosette-forming lymphocytes was substantially diminished 
with a range of less than 1 to 29 percent compared to the normal range of 
60 to 70 percent. Thus all patients in this series had a prodominance of B- 
cells in peripheral blood. 
The absolute number of E-rosette-forming cells varied among patients. 
With the exception of patient 6, who had slightly diminished T-cell number, 
all patients had normal or increased counts. 
Immortalization (Table III) 
Within two to four weeks of inoculation with EBV, normal adult lymphocytes 
demonstrated transformation into continuous lymphoblastoid cell lines. In 
four tubes, each containing 8x10^ cells, acid production, clumping, and 
lymphoblastoid cells with "whisker-like" cytoplasmic processes were present. 
Uninoculated control cells did not survive. 
CLL cells, whether from patients with well or poorly differentiated 
disease were not immortalized upon exposure to EBV. Although several cultures 
showed clumping and acid production initially, within six weeks most cells 
were pyknotic. Spontaneous transformation did not occur in uninoculated 
cultures. Cells from patient #6 were still viable after 6 weeks and formed 
small clumps but without morphologic change. Two tubes were subdivided 
27 
. • OX.TRCT 3 
; , * 'in T!/0"i 
but failed to survive. In conclusion, within the limitations of the culture 
system employed, CLL cells were completely resistant to transformation by 
EBV and did not transform spontaneously. 
Stimulation of Cellular DNA Synthesis 
Stimulation of DNA synthesis in normal and leukemic lymphocytes by EBV, 
UV-inactivated EBV (DV-EBV), and PHA was determined by comparing the in- 
7 
corporation of H-Tdr in experimental and control cultures. Arbitrarily, 
a net stimulation of greater than 1000 counts per minute (cpm) was considered 
to indicate unequivocal stimulation. 
A. Stimulation of Normal Lymphocytes 
The addition of biologically active EBV to normal adult lymphocytes 
resulted in increased DNA synthesis which was first detected 5 or 6 days 
following inoculation (Table IV). In two experiments inoculated lympho¬ 
cyte cultures which exhibited increased DNA synthesis showed morphologic 
evidence of immortalization one or two weeks later. UV-inactivated virus 
had no stimulatory effect, although the donor of the cells was EBV-seropos- 
itive. Cells incubated with PHA showed a marked increase in ^IITdr incorpor¬ 
ation which reached a peak 3 to 5 days after initiating the culture and 
which declined thereafter. This pattern of rapid induction of DNA synthesis 
followed by a decline is consistent with the response pattern of normal 
lymphocytes to PHA described by others (Greaves et al_. , 1974) . 
B. Stimulation of Leukemic Cells from Patients with Well-Differentiated CLL. 
Serial stimulation assays were performed on lymphocytes from patients 
with well-differentiated CLL (Patients #1-6). Three patterns of response 
were observed: 1) No stimulation of DNA synthesis by EBV or UV-EBV; 2) 
Stimulation by EBV alone: or 3) Stimulation by both EBV and IJV-EBV. The 
results are shown in Table V. 
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1) Cells from three patients (#1,3,4) were completely unresponsive to 
either EBV or UV-EBV; net stimulation did not exceed 64 cpm. Furthermore, 
in contrast to normal lymphocytes, baseline DNA synthesis in this group 
did not increase with time in vitro. The response to PHA was variable. 
Cells from patients #1 and 3,, both having a diminished percentage of 
T-cells but a normal absolute number, were stimulated by PHA. In compari¬ 
son to normal lymphocytes, the onset of the response was delayed (day 6 vs. 
day 3) and the net stimulation was lowered (approximately 1000 cpm vs. 
4300 cpm in the normal). By contrast, cells from patient #4, who had an 
absolute increase in T-cells, displayed no response to PHA. 
The results with cells from patient #2 were equivocal. Net increase 
of 263 and 476 cpm were present respectively in EBV and UV-EBV exposed 
cultures on day 6. However, the results in this experiment are marred by a 
wide variability in replicate values (greater than 30%), apparently a conse¬ 
quence of uneven distribution of cells in replicate tubes. 
2) Cells from patient #5 were stimulated by EBV with a significant 
increase in isotope incorporation on days 10 and 14. UV-EBV produced no 
stimulation but appeared to be somewhat inhibitory. Baseline DNA synthesis 
increased during the time of incubation. The PHA response was intact. The 
pattern of response, stimulation by EBV but not by UV-inactivated virus, 
strongly suggested virus stimulation rather than response to antigen. 
However, since the EBV inoculated cultures failed to immortalize, the 
process remains undefined. 
3) The lymphocytes of patient #6 were stimulated by both EBV and 
UV-EBV. On day 6 of experiment AA40 (Table V) the net stimulation induced 
by EBV was approximately 1000 cpm compared to an increase of 3000 cpm in 
UV-EBV inoculated cultures. PHA had little effect on this patient's cells. 
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C. Stimulation of Cells from a Patient with Lymphosarcoma Cell Leukemia 
Leukocytes from patient #7 who had a significant proportion of poorly 
differentiated cells were extensively tested on three occasions. (Table VI). 
In experiments BB42 and AA82, addition of UV-inactivated virus stimulated 
DNA synthesis with a peak increase of 2000 to 3000 cpm occurring on day 10 
with a decline thereafter. In the third experiment (BB71), the peak increase 
on day 10 was about 900 cpm. 
Biologically active EBV also stimulated significant isotope incor¬ 
poration with a peak increase either on day 10 or day 14. The response to 
PHA was variable in the three experiments and suggested that the population 
of responding cells was different in each test. In fact, the greatest 
response to PHA (4500 cpm in Expt. BB42) correlated with the presence of 
the greatest number of T cells. (Table II). The degree of stimulation by 
EBV and UV-EBV did not correlate with PHA responsiveness. 
The trend of the data, transitory stimulation by EBV and UV-EBV without 
immortalization by live virus suggested that the stimulation was a con¬ 
sequence of recognition of antigen. To corroborate this conclusion, an 
experiment was performed in which human serum containing antibody to EBV 
(anti-VCA titer of 1:160) was added to virus inoculated cultures on day 0 
and the ensuing isotope incorporation compared with that in similar cultures 
containing human serum without EBV antibody. Addition of specific antibody 
is known to inhibit immortalization and immortalization-related DNA 
synthesis but not the DNA stimulation secondary to antigenic stimulation. 
*7 
(Gerber and Lucas, 1972b). On day 10 net H-Tdr incorporation by cells 
exposed to UV-EBV was 2000 cpm in cultures with and without EBV-specific 
antibody* 
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EBV induced net stimulation was not inhibited by the addition of anti¬ 
body. On day 10, net stimulation was 5500 cpm in antibody-containing 
cultures compared to 3700 cpm in antibody-negative cultures. The inability 
of specific antibody to diminish the stimuli effect of EBV and UV-EBV thus 
suggest the mechanism of stimulation to be immunologic in nature. 
Antibody did not inhibit stimulation by EBV. Ten days after inocu¬ 
lation with virus, cultures incubated with antibody showed a net 'dl-Tdr 
incorporation of 5500 cpm while cultures without antibody incorporated 
3700 cpm. 
Comparison of Stimulation of T- and B-Lymphocytes 
Since the lymphocytes from patient #7 with poorly differentiated CLL 
were consistently stimulated by both EBV and UV-EBV, an attempt was made to 
determine whether the stimulation was occurring primarily in cells with B- 
or T-lymphocyte markers. Mixed leukocytes were incubated with sheep red 
blood cells to form E-rosettes and then separated on a Ficol1-Mypaque gradient 
to yield E-rosette enriched (T-enriched) and E-rosette-depleted (T-depleted) 
fractions. Cultures of each fraction were set up, inoculated, and serial 
pulses performed. 
The fractionation procedure was effective in selectively distributing 
the E-rosette forming cells although the percentage of EAC-rosette-forming 
cells remained high in the T-enriched fraction. (Table VII). 
The response of the lymphocyte subpopulations to EBV, UV-EBV and PHA 
is summarized in Table VIII. Spontaneous DNA synthesis in uninoculated 
cultures of the T-cell enriched subpopulation was low in comparison to the 
T-cell depleted subpopulation or the unfractionated cells (data shown in 
Table VI, Expt. BB42). Cells depleted of T-lymphocytes were not stimulated 
by PH\. An increase in DNA synthesis in the E-enriched fraction was observed 
(800 cpm net); however, this stimulation was far less than that observed in 
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the unfractionated cells (4500 cpm, Table VI). The data suggest that the 
fractionation procedure may have altered the ability of the T-lymphocytes 
to respond. 
EBV inoculation produced significant stimulation of the T-cell enriched 
fraction but had an equivocal effect (500 cpm) on the T-depleted population. 
UV-EBV inoculation resulted in slight stimulation of the T-enriched fraction 
but moderate stimulation of the T-depleted fraction. These results are in¬ 
consistent with one another given the reasonable assumption that antigen 
recognition of EBV and UV-EBV involves the same lymphocyte subpopulation. 
Further experiments, particularly auto-radiography, are necessary to identify 
the cell type stimulated by UV-EBV. 
EBV Antibody Titers 
Anti-VCA antibodies were present in the sera of all CLL patients. 
(Table IX). The titers ranged from 1:10 to greater than 1:160. Anti-EA 
antibodies were also present in five CLL patients and ranged in titer from 
1:20 to 1:400. On the basis of the presence or absence of antibodies to EA, 
the patients could be divided into two categories: 
1. Patients #1,2, and 3 had no detectable anti-EA. Patient. #2 did 
have an anti-VCA titer of 1:80 to 1:160, whereas the other patients had low 
titers. Although paired sera were available in only one case, a reasonable 
explanation for the presence of anti-VCA antibody would be previous EBV 
infection. 
2. Patients #4,5,6, and 7 had antibodies to EA perhaps indicating 
ongoing or recent EBV infection. Paired sera, obtained four to six weeks 
later, were available from patients #6 and 7 and showed no change. As 
expected, the anti-VCA titers were also elevated. 
The presence in patient #7 of a very high titer of anti-EA (1:400), 
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comparable to that observed in EBV-associated malignancy, was intriguing. 
This patient unlike the others had CLL with poorly differentiated cells. 
Serum obtained from patient #8, also with a poorly differentiated CLL, was 
tested and found to have an elevated anti-VCA and an anti-EA titer of 1:400. 
Further samples from similar patients were not available. 
There was no strict correlation between the presence of antibody 
stimulation of lymphocytes by either EBV or UV-EBV (Table X). Lymphocytes 
from patients #6 and #7, who had anti-EA and anti-VCA, were stimulated. 
However, cells from patient #4 with a titer of anti-EA of 1:80 were not 
stimulated. Failure to observe antigenic stimulation in patients (2, #4) 
with EBV antibody may be a consequence of impaired T-lymphocyte function. 
Consistent with this hypothesis is that PHA did not stimulate the cells of 
these patients. However, it should be noted that the normal leukocytes 
obtained from a seropositive donor (anti-VCA of 1:20) did respond to UV- 
inactivated EBV. These data are in conflict with those of Gerber and Lucas 
(1972b) who reported stimulation of DNA synthesis by UV-treated virus in 
leukocytes of seropositive individuals. 
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Discussion 
Failure to Stimulate or Immortalize CLP Cells with EBV: 
The purpose of this study was to determine whether lymphocytes from 
patients with chronic lymphocytic leukemia were susceptible to EBV induced 
stimulation of DNA synthesis and immortalization. Peripheral mononuclear 
cells from seven CLL patients were inoculated with EBV. In no case could 
lymphoblastoid cell lines be established. By contrast normal adult leukocytes 
invariably form lymphoblastoid cell lines when cultured in the presence of 
EBV. In four of the seven patients stimulation of DNA synthesis by EBV was 
not observed. In another two patients stimulation of DNA occurred in cells 
exposed to EBV. However, this increase in isotope incorporation was trans¬ 
ient and was not accompanied by morphologic changes suggesting lymphopro- 
liferation. Since DNA synthesis in these cells was also induced by UV- 
inactivated virus, it appeared that stimulation resulted from a response of 
sensitized cells (presumably T-cells) to F.BV-antigens. Only in one patient 
(#5) did an increase DNA synthesis occur in the presence of biologically 
active EBV but not in the presence of UV-treated virus. The results in 
this case are problematic. Conceivably the stimulation of this patient's 
cells was due to a direct effect of the virus, e.g., an "abortive trans¬ 
formation". However, such an abortive infection has never been described 
in any EBV system. It is more likely that a technical error was responsible 
for the failure of UV-inactivated EBV to stimulate the cells of this patient. 
The cells of this patient deserve further study. It would be of interest 
for instance to look for the induction of EBV related antigens (EBNA, EA) 
in these cells. 
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In general, the CLL cells appeared resistant to EBV infection. 
Henderson performed a conventional microwell transformation assay on lympho¬ 
cytes from patient #2 and did not observe any transformation. (Henderson, 
unpublished data.) Addition of PHA and lipopolysaccaride which have been 
shown to potentiate transformation in cord blood leukocytes had no effect. 
(Henderson et_ aj_. , 1977a). 
Since the mechanisms of immortalization are poorly understood, the 
reasons for the failure of the CLL cells to respond to EBV are a matter of 
speculation. EBV receptors have been described on the surface of lympho¬ 
cytes bearing surface immunoglobulin and complement receptors. (Jondal 
and Klein, 1973; Greaves et_ a_l_. , 197$). Whether CLL cells have receptors 
is controversial. Gergely et al. (1974) found that EBV-producer productive 
cells which are known to bear virus envelope-related membrane antigen were 
capable of forming rosettes with CLL cells. They concluded that CLL cells 
must, therefore, have receptors for EBV. However, binding by some other 
receptor (e.g. immunoglobulin receptor) was not ruled out. Greaves et al. 
(1975) were unable to demonstrate receptors on CLL cells using an indirect 
immunofluorescence assay. 
In preliminary experiments, mitomycin treated T-cell depleted CLL 
lymphocytes were incubated with EBV. Free virus was washed off and the 
prepared cells placed in culture with autochthonous T-enriched cells. 
The T-lymphocytes from this sero-positive individual were stimulated. 
(Robinson, unpublished data). This result suggests that B-lymphocytes from 
a CLL patient are capable of binding virus. Further work with this approach 
may distinguish whether CLL cells do have EBV receptors. 
The failure of CLL cells to be stimulated by virus may also be re¬ 
lated to the generally poor response of these cells to mitogens described 
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in the introduction. Abnormalities of the membrane, energy metabolism, DNA 
synthetic enzymes and other cellular functions have all been invoked to 
explain CLL cell unresponsiveness to certain mitogens. (Theml et al., 1976). 
Any and all of these abnormalities could be relevant to EBV induced stimu¬ 
lation. 
Immunologic Recognition of EBV by CLL or Lymphocytes 
UV-inactivated EBV stimulated DNA synthesis in lymphocytes from two 
patients with CLL suggesting that a subpopulation of cells was capable of 
recognizing EBV as an antigen. The response was transitory and was not 
inhibited by the addition of EBV specific antibody. Several additional 
experiments should be done to characterize this stimulation. The nature of 
the responder population of cells has not been clearly established by the 
results reported in this study. Autoradiography in combination with rosette 
tests should distinguish whether cells stimulated into DNA synthesis are 
T (E-rosette-forming) cells or B (EAC-rosette forming) cells. It would 
also be of interest to determine whether EBV-related antigens can be induced 
in CLL cells. 
Lymphocyte stimulation assays for cell-mediated immunity to viruses 
have been described for a large number of viruses including other herpes 
viruses. (Bellanti et al., 1976). However, the previously quoted study by 
Gerber and Lucas (1972b)is the only published study on the response of 
lymphocytes from sero-positive individuals to UV-inactivated EBV. The 
results of the present study are in conflict with their data since normal 
lymphocytes from a sero positive individual were not stimulated by 
inactivated virus. However, the stimulation of DNA synthesis by inactivated 
EBV in lymphocytes from several CLL patients suggests a response to antigenic 
stimulation and, thus, partially corroborates their data. 
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Significance of Anti-EA Antibodies in CLL 
The most intriguing observation of this study was the finding of elevated 
titers of EBV specific antibodies, particularly anti-EA in these patients 
with CLE. As described in the introduction, such titers have been observed 
before without good explanation. It has been proposed that the elevated 
titers are a consequence of immunosuppressive effects of the disease or 
therapy. (Henle and Henle, 1975). However several studies have shown no 
correlation between depression of cell-mediated immunity and elevated antibodies 
to EBV. (Hesse et al., 1973; Levine et al., 1975). 
The current opinion, repeated in virtually every paper concerning anti¬ 
bodies to EA, is that the antibody is associated only with current or 
recent infection with EBV and is "rare" in normal individuals. Those normal 
individuals who do have anti-EA have not been characterized. Are such 
people inapparently infected or prolonged excreters of EBV and presumably 
constantly antigenically stimulated or can anti-EA persist without continual 
stimulation? 
Titers of anti-EA greater than 1:160 have not been described in "normal" 
individuals and are unusual even in patients with acute mononucleosis. Thus 
the finding of two patients with titers of 1:400 comparable to that seen 
in BE and NPC was extraordinary. A comparison of white count, stage, treat¬ 
ment, transfusions, and complications failed to show any consistent difference 
between patients with anti-EA and those without. (Tables 1, X). One 
apparent difference was that both patients with very high anti-EA titers had 
a significant increase in the proportion of circulating poorly differentiated 
cells. The failure to observe a correlation of anti-EA with adenopathy 
(Stages I, III, IV) deserves comment. It has been proposed that the titer 
of anti-EA (or at least anti-D) correlates with nodal involvement. (Henle 
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and Henle, 1975), In CLL anti-EA, when present, is said to be primarily 
anti-D. However, despite an assertion to the contrary (Henle and Henle, 1973) 
there has been no published evidence that CLL patients with enlarged nodes 
are more likely to have anti-EA. In this study, it was difficult to deter¬ 
mine from a chart review the extent of the adenopathy in each patient. 
However, patient #2 had adenopathy and massive splenomegaly and yet did not 
have anti-EA whereas patient #5 lacked adenopathy and did have anti-EA. A 
larger sample of course is necessary to draw further conclusions. 
The apparent correlation of high titers of anti-EA with poorly 
differentiated CLL requires further investigation. There are no reports on 
antibody titers in this syndrome. .Tohannson et al. (1971) in a study have 
argued that the anti-VCA titers are higher in poorly differentiated lympho¬ 
cytic lymphoma than in well differentiated lymphoma. However their analysis 
has been disputed, (Goldman, 197 2) 
The small number of patients and short follow-up time have made it 
impossible to correlate severity of disease and survival with anti-EA titer 
as has been done with NPC. The two patients in this study with high titers 
of anti-EA and poorly differentiated cells have had severe disease. 
Elevated antibody titers to EA may identify a sub-group of patients with CLL. 
37 
/ \ ->d 'Af d srroii.i 
- Mi b *' j.■- -; teq tidvawoH 
• J i-i3-r;» ?vsri 
■ 
■ 
Summary 
Lymphocytes from 6 patients with chronic lymphocytic leukemia (CLL) 
and one patient with chronic lymphosarcoma cell leukemia (CLSL) were 
inoculated with Epstein-Barr virus (EBV) and observed for evidence of 
stimulation of cellular DNA synthesis and immortalization. With inocula 
of undiluted stocks of B95-8, immortalization did not occur. Stimulation 
3 
as measured by net incorporation of Htritiated thymidine occurred in 
cells from two patients. The increased DNA synthesis appeared to be a 
consequence of recognition of the virus as antigen since stimulation 
was also induced by ultraviolet-irradiated virus. 
Antibodies to EBV viral capsid antigen were present in all patients 
and did not correlate with in vitro stimulation. Antibodies to EBV early 
antigen, (EA), consistent with ongoing EBV infection, were present in 
several patients. Two patients with poorly differentiated lymphocytic 
leukemia cells had very high titers of anti-F.A comparable to levels seen 
in EBV-associated tumors. The significance of these titers in CLL as 
well as the apparent resistance of CLL cells to EBV infection are dis¬ 
cussed. 
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TABLE II. ABSOLUTE NUMBER OF EAC AND F. ROSETTE FORMING CELLS. 
f 
Patient Expt. # 
3 
Lymphocytes/mm % EAC Rosetts 
(Absolute It /mm^)a 
% E Rosettes 
(Absolute # /mm^) 
1 AA28 133,400 67 (89,400) 4 (5300) 
AA81 173,400 73 (126,900) 41 (41700) 
2 AA61 119,700 87 (104,100) 2 (2400) 
3 AA83 192,900 84 (162,000) 1 (1900) 
4 BB1 162,200 91.5 (148,000) 7 (11,400) 
5 AA71 13,100 75 (9800) 29 (3800) 
6 AA40 6100 87 (5300) 15 (900) 
BB41 7600 90.5 (6900) 9.5 (700) 
7 AA82 71,500 76 (54,300) 5 (3600) 
BB42 108,900 76 (82,800) 7.5 (8200) 
BB71 101,200 80 (81,000) 3 (3000) 
8 JR-1 504,600 
Normal 35 58.5 
Adult 33 57 
Asteldi et al. (1975) 10 to 30 60 to 70 
Han et al. (1976) 23 (350 + 130) 64 (1600 + 372) 
a- 
Absolute # of rosette forming cells = % rosette forming cells X lymphocytes/mmJ 

TABLE III. IMMORTALIZATION OF NORMAL AND CLL LYMPHOCYTES 
Normal Lymphocytes‘ 
CLL Lymphocytes^ 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
Immortalization 
(# of lines established/attempts) 
F.BV-Inoculated Controls 
4/4 0/4 
0/4 0/4 
0/2 0/2 
0/2 0/2 
0/2 0/2 
0/2 0/2 
0/4 0/6 
0/6 0/6 
8x10^ cells incubated with virus or medium in each tube 
2x106 cells per culture except #5 where only 10^ cells were available. 
43 
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TABLE IV. STIMULATION OF DNA SYNTHESIS IN NORMAL LYMPHOCYTES 
Expt. # Daya Baseline DNA 
c 
Net Stimulation 
Synthesis0 EBV UV-EBV PHA 
BB24 3 5 85 (-67) ND 4313d 7637e 
6 2004 817 ND 1646 2155 
13 1476 2002 ND 695 (-810) 
JR1 3 563 222 6 - 14130 
5 1227 1826 103 - 1483 
7 3548 4932 (-313) - (-2270) 
a. 
Days after inoculation 
b_ 
Mean cpm of duplicate cultures. Unless otherwise noted, replicate 
valves were within 10% of the mean, 
c 
Mean cpm of inoculated culture minus baseline DNA synthesis 
d. 
25yug/ml of PHA 
2.5 yUg/ml of PHA 
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TABLE V. STIMULATION OF CELLS FROM PATIENTS WITH WELL DIFFERENTIATED CLL 
Patient Expt. # Day Baseline DNA Net Stimulation 
Synthesis EBV UV PHA 
1 AA81 3 219 (-12) 58 -219 
6 230 18 53 1114 
10 208 55 -64 232 
14 160 64 (-17) (-30) 
2 AA61 3 471 — 540bs 
6 436 268c 476c 628 C 
10 118 179c 100c - 
3 AA83 3 198 (-15) (-18) 10a 
6 373 (-79) (-97) 962 
10 404 9 (-203) 288 
14 286 (-43) (-116) (-22) 
4 BB1 3 150 29 (-4) 52a 
6 249 9 (-27) 118 
10 175 (-26) (-42) 88 
14 118 14 6 3 
5 AA71 3 152 49 43 317a 
6 693 (-62) (-308) 7182 
10 1338 1091 (-340) 2293 
14 1122 1037 (-310) 2428 
6 AA40 1 760 (-239) 155 644b 
3 413 476 532 246 
6 1180 1025 2925 288 
a 
25pg PI 1 A/ml 
b 
50jug PIIA/ml 
c 
Difference in replicates >10% of mean. 
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TABLE VI. STIMULATION OF CELLS FROM A PATIENT WITH POORLY DIFFERENTIATED CLL 
Patient F.xpt. # Day Baseline DNA Net Stimulation 
-- - — ~Sy'ntTTsiT- THW--UT-TTW-fTO 
AA82 3 432 11 137 (-73)3 
6C 2707 (-806) 1545 (-1125) 
10 1384 805 3030 650 
14 2693 1191 (-393) (-1100) 
BB42 3 344 76 78 70b 
6 1107 57 1165 4442 
10 1233 1574 2179 4689 
14 1005 250 -261 239 
BB71 3 439 (-25) (-29) 
x
s
 
C
C
 
6 1760 170 894 531 
10 1508 1242 885 188 
14 871 (-266) (-517) (-287) 
BB42 3 283 230 43 _ 
(Ab +)a 6 914 811 255 - 
10 1202 5509 1937 - 
14 2278 3348 . (-556) - 
BB42 3 373 38 47 - 
(Ab -)e 6 828 (-82) 220 - 
10 1225 3665 2151 - 
14 1962 2526 (-253) - 
25pg PHA/ml 
b 
2.5^ug PHA/ml 
c 
Faulty thermostat permitted increased incubation temperature during pulse 
d 
Addition of 5% (V/V) human serum with anti-VCA antibody (1:160) 
e 
Addition of 5% (V/V) human serum with no anti-VCA antibody 
46 
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TABLE VII. ISOLATION OF LEUKOCYTE SUBPOPULATIONS FROM PATIENT #7 
Extp. # Cell Type % E-Rosettes % EAC Rosettes 
BB42 Mixed 7.5 76 
T-depleted 1.5 86.5 
T-enriched 52.5 33 
BB71 Mixed 3 80 
T-depleted «1 78 
T-enriched 50 23 
47 
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TABLE VIII. STIMULATION OF LYMPHOCYTE SUBPOPULATIONS FROM PATIENT H7 
Expt._#_ Day Baseline DNA Net Stimulation (Mean cpm) 
Synthesis (Mean cpm) F.PV UV-EBV PHA 
BB42b 
T-depleted 3 198 43 (-7) (-23) 
6 1289 512 701 (-570) 
10 631 404 594 83 
14 414 373 233 (-90) 
T-enriched 3 136 87 13 077 
6 396 256 51 845 
10 256 1411 328 821 
14 200 239 (-46) 279 
BB71 
T-depleted 3 234 48 (-7) (-80) 
6 1396 93 744 (-489) 
10 917 (-57) 738 (-389) 
14 889 (-57) (-89) (-731) 
T-enriched: Not done because of insufficient number of cells. 
a2.5 jug PHA/ml 
b 
3 
H-Tdr incorporation data for the unseparated population is 
shown in Table VI (Expt. BB42). 
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TABLE IX. F.BV-SPECIFIC ANTIBODY TITERS 
Patient Expt. # Anti-VGA Titer Anti-EA Tit 
1 AA28 1:20 ND 
AA81 1:20 41:10 
2 AA61 1:80 
1:160 
41:10 
3 AA83 1:10 <1:10 
4 BBI >1:160 1:80 
5 AA71 1:40 1:20 
1:40 
6 AA40 1:80 1:80 
BB41 1:40 1:80 
7 AA82 >1:160 >1:160 
1:400 
BB42 >1:160 
8 JR-1 >1: 160 >1:160 
1:400 
. lympho- 
donor BB24 1:20 41:10 
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A ppendix 

Consent Form for Participation in a Clinical Investigation Project 
Yale University School of Medicine 
Yale - New Haven Hospital 
Description of Project: 
We are investigating a virus called Epstein-Barr Virus which is the 
cause of infectious mononucleosis. This virus appears to infect only lympho¬ 
cytes (white blood cells). We are interested in learning the response of 
lymphocytes from patients with your disease to this virus. We ask your 
permission to draw a sample of blood. Participation in this study will not 
affect your current therapy and participation is entirely voluntary. You are 
free to refuse to participate and in the event you do this decision would have 
no effect on your relationship with your physician or the Medical Center staff. 
Authorization: I have read the above and decide that. 
(name of subject) 
will participate in the project described above. Its general purposes, the 
particulars of involvement and possible hazards and inconveniences have been 
explained to my satisfaction. My signature also indicates that I have received 
a copy of this consent form. 
Signature 
Relationship (self, parent, guardian, etc.) 
Date 
Signature of Principad. investigator Telephone 
or 
Signature of Person obtaining consent Telephone 
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